Pharma: Clinic Roundup
• Boehringer Ingelheim Pharmaceuticals Inc., of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, reported Phase III results for Tradjenta (linagliptin) 5 mg once-daily, which showed significant hemoglobin A1c reduction of 0.88 percent compared with 0.24 percent in the placebo group at 24 weeks.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST